Your session is about to expire
← Back to Search
GVHD Prophylaxis After Bone Marrow Transplant for Blood Cancers
Study Summary
This trial is asking people with blood cancer who need a bone marrow transplant to join, to find new ways of preventing severe side effects.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am of childbearing age and have a negative pregnancy test.I have been diagnosed with secondary acute myeloid leukemia.I have been diagnosed with myelodysplastic syndrome.I am 12 years old or older.I have had a stem cell transplant before.My leukemia is in its first remission and considered high risk.I have a donor who is a perfect match for me.My Non-Hodgkin's lymphoma is not in its first remission or is resistant to treatment.My leukemia is of a mixed or unclear type.My stem cell transplant will use cells from my blood.I have latent tuberculosis confirmed by a TB blood test.My brain leukemia was treated and is now in complete remission.My condition is NK cell leukemia and I am in remission.I have been diagnosed with Juvenile Myelomonocytic Leukemia.I do not have a severe infection that would prevent me from having a bone marrow transplant.I have chronic myelogenous leukemia.My kidney function, measured by creatinine clearance or GFR, is good.I am mostly able to care for myself and carry out normal activities.My lung function is above 50% of what's expected, or I can breathe well without extra oxygen.My Hodgkin's disease is not in its first remission or is not responding to treatment.My genetic testing shows a specific mismatch in my DPB1 gene.My condition is either newly diagnosed AML, AML in or beyond first remission, relapsed, refractory, or I have myeloid sarcoma.My leukemia has returned after the first treatment.
- Group 1: ArmA- Lymphoid
- Group 2: ArmB-Myeloid
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has ArmA-Lymphoid received regulatory authorization from the FDA?
"Given that ArmA-Lymphoid is a Phase 2 trial, and thus lacks evidence of efficacy but does have some data indicating safety, our team at Power has assigned it a score of two."
How many participants are actively engaged in this clinical experiment?
"Affirmative. Clinicaltrials.gov reflects that this clinical trial is currently enrolling patients, starting from the 4th of November 2022 and updated as recently as the 7th of November 2022. There are 32 positions available at a single medical facility."
Are there any vacancies left to join this clinical experiment?
"Affirmative. Details available on clinicaltrials.gov demonstrate that the trial, which was published on November 4th 2022 is actively enrolling individuals. Specifically, 1 research site requires 32 volunteers to participate in this project."
Share this study with friends
Copy Link
Messenger